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Epidemiology and outcome of myeloma are mainly reported fromlarge university centers and collaborative groups, and do not repre-sent 'real-world' patients. The Swedish Myeloma Registry is a
prospective population-based registry documenting characteristics, treat-
ment and outcome in newly diagnosed myeloma, including asympto-
matic and localized forms, with the purpose of improving disease man-
agement and outcome. This report presents information on patients diag-
nosed between 2008 and 2015, including data on first-line treatment in
patients diagnosed up to 2014, with a follow up until December 2016. We
present age-adjusted incidence, patients' characteristics at baseline, treat-
ment, response, and survival. Baseline data were available with a 97%
coverage in 4904 patients (median age 71 years, males 70 years, females
73 years; 72% were 65 years or older), and at 1-year follow up in 3558
patients with symptomatic disease (92% of patients initially reported).
The age-adjusted incidence was 6.8 myeloma cases per 100,000 inhabi-
tants per year. Among initially symptomatic patients (n=3988), 77% had
osteolytic lesions or compression fractures, 49% had anemia, 18%
impaired kidney function, and 13% hypercalcemia. High-dose therapy
with autologous stem cell transplantation was given to 77% of patients
aged up to 66 years, and to 22% of patients aged 66-70 years. In the study
period, 68% received bortezomib, thalidomide, and/or lenalidomide as
part of the first-line treatment, rising from 31% in 2008 to 81% in 2014.
In active myeloma, the median relative survival of patients aged 65 years
or under was 7.7 years, and 3.4 years in patients aged 66 years and over.
Patients diagnosed with myeloma in more recent years were associated
with significantly higher rates of complete or very good partial remission
(P<0.05), and with a significantly higher survival, with a Hazard Ratio
(HR) of 0.84 (95%CI: 0.77-0.92; P<0.05). There was a small, but significant
survival benefit in patients treated at university hospitals (HR 0.93;
95%CI: 0.87-0.99; P<0.05). We report here on a near complete 'real-world'
population of myeloma patients during an 8-year period; a period in
which newer drugs were implemented into standard practice. The overall
incidence and median age were both higher than in most previous studies,
indicating a more complete coverage of older patients. Myeloma survival
in Sweden is comparable to other large registry studies, and responses and
survival improved during the study period. 
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ABSTRACT
Introduction
Over recent decades, new treatment options have
emerged in myeloma, with great expectations of
improved survival. The introduction of high-dose melpha-
lan with autologous stem cell support (HDM-ASCT) and
newer drugs, such as the immunomodulatory agents
(thalidomide, lenalidomide, and pomalidomide), protea-
some inhibitors (bortezomib and carfilzomib), monoclon-
al antibodies, and other classes, has led to a rapid imple-
mentation of these drugs under international guidelines.1-7
To date, most studies on myeloma are based on selected
patients from large referral centers and collaborative
groups, with defined inclusion and exclusion criteria. But
these often omit elderly patients, and thus do not reflect
the true 'real-world' population.8 Also, there is limited
information available on the use of new therapies and
their efficacy and tolerability in standard practice, sup-
porting the need for representative population-based
prospective studies on characteristics, diagnostics, treat-
ment and outcome in myeloma patients.  
Survival data from cancer registries are available, but
often lack information on baseline characteristics and
treatment. EUROCARE, covering nearly 50% of patients
diagnosed with plasma cell neoplasms in Europe in the
period 2000-2007, reports an age-standardized 5-year rel-
ative survival (RS) of 39.2%, an increase from 29.8% in
1997. Outcome was significantly better in the younger
patients (68.6% vs. 21.8% 5-year relative survival), and in
women (40.4% vs. 38.1%).9 These results have later been
confirmed by other cancer registry data.10-12 
A 2010 Swedish  study of  retrospective data regarding
baseline characteristics and treatment of consecutive
patients in Malmö found a similar trend in improved sur-
vival, which correlated with the introduction of new treat-
ment modalities.13,14
The Swedish Myeloma Registry was established in
2008, and the first Swedish guidelines on diagnostics and
treatment of myeloma were published in 2010. This is the
first report on our population-based data on characteris-
tics, treatment and survival in Swedish myeloma patients
diagnosed from January 2008 through December 2015.
Methods
The Swedish Cancer Registry 
The Swedish Cancer Registry is a nation-wide compulsory
dual-report system developed in 1958, which is supported by the
personal identification code system used for all Swedish citizens
which was established in 1947. First, all pathology specimens indi-
cating malignancy are reported by the pathologist to the Regional
Tumor Registry. Second, data on date and type of cancer diagnosis
of all patients with a newly diagnosed cancer are reported by cli-
nicians, with missing data actively requested to secure a high level
of completeness. In a validation study, the completeness (95%)
and diagnostic accuracy (98%) of the Swedish Cancer Registry
was found to be very high for multiple myeloma patients.15 
The Swedish Myeloma Registry
The Swedish Cancer Registry comprises web-reported clinical
and laboratory data on all patients diagnosed with active myelo-
ma, smoldering myeloma, plasma cell leukemia, and solitary bone
and extramedullary plasmocytomas in Sweden since 2008, at time
of diagnosis and after a 1-year follow up. Coverage is analyzed
through the compulsory Swedish Cancer Registry. Survival data
are obtained  from the Swedish Population Registry. Patients diag-
nosed by autopsy are included in the Swedish Cancer Registry,
but not in the Swedish Myeloma Registry. The registry is publicly
financed, and the patients are reported by treating physicians and
nurses. Courses are held for those responsible for reporting patient
data to assure coherent reporting in all regions and hospitals.
These courses cover inclusion criteria, parameters, and the manual
of the Swedish Myeloma Registry.   Criteria for the diagnosis of
active myeloma (MM), smoldering myeloma (SMM), plasmocy-
toma, and plasma cell leukemia are defined according to the
International Myeloma Working Group (2003).16 Other gam-
mopathies, such as monoclonal gammopathy of undetermined
significance (MGUS) and AL-amyloidosis are not included in the
registry. Age-specific incidence, age distribution at diagnosis,
median time from diagnosis to registry report, and distribution of
the diagnoses in the registry are reported. Adherence to treatment
guidelines concerning diagnostics and ISS-staging (International
Staging System) is checked by studying the use of different diag-
nostic tools such as bone marrow sample, cytogenetics including
fluorescence in situ hybridization (FISH), β 2-microglobulin (β2m)
and s-albumin. Baseline characteristics at diagnosis are collected,
including M-protein isotype, percentage of plasma cells in the
bone marrow, serum free-light chain (FLC), and laboratory param-
eters capturing CRAB criteria (CRAB; Calcium, Renal insufficien-
cy, Anemia or Bone lesions). One year after diagnosis of sympto-
matic MM, data on first-line therapy, occurrence and date of first
relapse or complications are requested. The study was performed
in agreement with the ethics committee of Stockholm and the
Swedish Society of Hematology. 
Treatment of MM in Sweden 
In Sweden, patients with myeloma are typically diagnosed and
followed clinically by physicians at hospital-based hematology
centers, and no patients are seen at private hospitals. In the study
period, the treatment of MM was guided by the British/Nordic
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Table 1. Characteristics of active myeloma (MM) and smoldering
myeloma (SMM) patients in the Swedish Myeloma Registry.
Characteristics Patients
Total, n (%) 4904 (100%) 
Diagnosis, n (%)
Multiple myeloma 3988 (81.3%)
Smoldering multiple myeloma 916 (18.6%)
Age in years at dx, median 
All 71
Male 71
Female 73
Immunoglobuline class n (%)
IgG 2882 (58.8)
IgA 1033 (22.3)
Bence-Jones MM 688 (14.0)
Non-secretory MM 143 (2.9)
IgD 19 (0.4)
IgM 14 (0.3)
Not known 23 (0.5)                                              
More than one Ig 41 (0.8)
IgE 1 (0.0)
n: number; dx: diagnosis.
treatment program for multiple myeloma (2005),17 and the
Swedish 2010 National Guidelines  (up-dated in 2013). Briefly,
high-dose melphalan and autologous transplantation (HDM-
ASCT) was recommended as up-front treatment for all MM
patients aged 65 years or under, and in patients aged 66-70 years
if they had good performance status. In 2005, vincristine, adri-
amycin, and dexamethasone (VAD) or similar combinations were
recommended as induction treatment before HDM-ASCT, and
later, in the 2010 guidelines, bortezomib and thalidomide became
part of standard induction, following an introduction period sub-
sequent to  approval in 2004. Patients at smaller hospitals are, as a
rule, only referred to university hospitals for the ASCT procedure
and afterwards return to their hospital of origin. For patients aged
66 years and older, melphalan and prednisone (MP) or cyclophos-
phamide and dexamethasone (CyDex) was standard up-front
treatment until 2004 when melphalan, prednisone and thalido-
mide (MPT) was incorporated as a treatment option. In 2010,
MPT was the standard for patients not eligible for ASCT, and MP
and bortezomib (MPV) were treatment options.  In the 2013 ver-
sion, both MPT and MPV were standard up-front treatments in
those patients not eligible for ASCT.
Statistical analysis
Incidence was extracted from the Swedish National Board of
Health statistical database on cancer 1970-2015, which includes all
patients with the diagnosis ICD 203*.18 All other analyses were
performed on patients reported to the Myeloma Registry with a
97% coverage compared to the Swedish Cancer Registry.19 For
diagnoses of MM and SMM, we summarized descriptive statistics
at diagnosis. We tabulated categorical variables such as sex, Ig-
class and use of new drugs. Summary statistics, for example,
median and range, were calculated for continuous variables such
as age and β2M. The χ2 test was used as significance test of differ-
ence in proportions. Statistical analysis of treatment was only car-
ried out on MM patients with a reported 1-year follow up, includ-
ing patients who had developed  symptomatic disease after SMM
C.H. Blimark et al.
508 haematologica | 2018; 103(3)
Figure 1. Age distribution in the Swedish
Myeloma Registry in men and women in (A)
active myeloma (MM) and (B) smoldering myelo-
ma (SMM). n: number. 
Table 2. Prevalence of myeloma-related organ and tissue impairment
(ROTI) and International Staging System (ISS) stage at diagnosis in
patients with active myeloma at diagnosis in the Swedish Myeloma
Registry.
Patients
n=3988
ROTI (%)
Anemia* 49%
Renal impairment** 18%
Hypercalcemia*** 13%
Skeletal disease 77%
ISS stage (%)
Stage I 23
Stage II 44
Stage III 33
n: number; in patients with report on:  *anemia defined as hemoglobin < 10g/dL and
reduction of 2g/dL from the normal value; **renal failure defined as creatinine >173
mol/L; ***hypercalcemia defined as s-calcium (uncorrected) > 2.75 mmol/L or  ion-
ized calcium>1.45 mmol/L. 
A
B
or plasmacytoma. We estimated observed survival using the
Kaplan-Meier method. When estimating relative survival (RS), rel-
ative to the general Swedish population, we used the Ederer II
method for expected survival. For observed survival (OS), we esti-
mated Hazard Ratios (HR) using Cox proportional hazards regres-
sion modeling. Also for RS, we estimated HR using proportional
hazards regression, but in transformed time.20 Survival time was
calculated from date of diagnosis to death or censoring. Patients
were censored at the end of follow up in the study or loss to fol-
low up. Age-standardized RS was calculated in each age group
separately and then weighted together using weights from a stan-
dard population, in this case, the International Cancer Survival
Standard (ICSS) 1. We used a proportional hazard model of RS by
year of diagnosis in all patients to estimate changes in survival
over time. The survival analysis by year of diagnosis included both
SMM and MM, and the date of diagnosis refers to the date of the
primary diagnosis, whether this was SMM or MM. To evaluate
the impact of the treating hospital, we estimated a proportional
hazard model of RS by hospital type, in the categories “university
hospital” or “not”, and hospitals reporting treatment on more or
less than 10 patients per year. The survival analysis by treatment
response and by hospital type was carried out on symptomatic
MM patients only (including patients who had developed symp-
tomatic disease after SMM or plasmacytoma) with reported 1-
year follow up, to enable comparison with statistics on treatment.
When adjusting for ISS stage in regression analysis, we treated
patients with missing values in the stage variable as a category
within the ISS stage variable in order to not exclude the cohort of
patients with missing data on ISS stage. P<0.05 was considered
statistically significant. All data preparation and analysis were car-
ried out using R statistical software.21 
Results
A total of 5222 patients with plasma cell diseases diag-
nosed in the period 2008-2015 had been reported to the
Swedish Myeloma Registry as of December 31st 2016,
with 97% coverage when compared with the Swedish
Cancer Registry. 
Clinical data at diagnosis were available for 4904 MM
and SMM patients diagnosed in the period 2008-2015
Experiences from the Swedish Myeloma Registry
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Figure 2. Survival in active myeloma (MM) in the
Swedish Myeloma Registry: observed (A) and
relative (B) survival, by 10-year age cohorts. n:
number.
B
(Table 1), and at 1-year follow up for 3558 of all MM cases
diagnosed 2008-2014, being 92% of all MM initially
reported 2008-2014. Data were reported from 74 different
centers in Sweden, approximately 40% from university
hospitals, and 60% from regional and smaller hospitals, all
public care institutions. The median time of follow up of
all SMM and MM patients was 4.9 years.
The total crude and age-adjusted (to the population in
Sweden in the year 2000) incidence was 7.0 and 6.8 cases
per 100,000 inhabitants, respectively (8.0 and 8.2 for men,
and 6.0 and 5.3 for women per 100,000 inhabitants,
respectively). The corresponding incidences for European
and World standard populations are 4.8 and 3.2, respec-
tively. Due to the difference in age distribution in the pop-
ulation, the total number of women was higher in the
cohort aged over 85 years (Figure 1). However, the age-
specific incidence was higher amongst men in all ages, and
the difference increased with advancing age (Online
Supplementary Figure S1). The median age of patients
reported to the registry with a diagnosis of MM or SMM
was 71 years (70 years for men and 73 years for women;
71 years for all MM and 72 years for all SMM). Twenty-
four percent of patients were 80 years or older at the time
of diagnosis. Notably, the percentage of patients aged
under 65 years was 28.3%;  61.4% of these were men and
38.6 women. 
Baseline characteristics 
Serum protein electrophoresis was performed in 99.5%
of all patients and a skeletal survey was performed in
97%. A bone marrow sample was taken in 97% of
patients at diagnosis, with a median of 27% plasma cells
in MM patients and 15% in SMM. Among patients with
MM at diagnosis (n=3988), 77% had reported osteolytic
lesions and/or compression fractures at diagnosis, and this
did not increase  over the study period. Anemia was seen
in 49%, renal insufficiency (s-creatinine >173 μmol/L) in
18%, and creatinine levels more than 110 μmol/L were
reported in 33% of MM patients. Hypercalcemia was
reported in 13% of MM patients at the time of diagnosis
(Table 2). The number of patients aged 80 years and under
who had FISH performed at diagnosis increased over the
study period, from 30% in the period 2008-2010, to 43%
in 2011-2015. Staging according to the ISS was reported in
71% of patients with MM in the study period. In MM
patients with reported ISS-stage, 23% were ISS stage I,
44%  stage II, and 33% stage III (Table 2).
Treatment
Of all patients with reported follow up, 77% of patients
aged 65 years or under at diagnosis and 5% of patients
aged over 66 years received HDM-ASCT as first-line treat-
ment. In patients aged 66-70 years, HDM/ASCT was per-
formed in 22%. Allogeneic transplantation as part of first-
line treatment was performed in only 1% of patients in
C.H. Blimark et al.
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Table 3. Proportion of patients who received novel drugs (thalidomide, bortezomib or lenalidomide) as first-line line treatment among active
myeloma patients with reported follow up, by year of diagnosis and by age  group (-65, 66–80, >80) years in the Swedish Myeloma Registry.
Patients All ages ≤65 years 66-80 years >80 years
with novel n=2400 n=913 n=1212 n=275 
drugs first line (%) (%) (%) (%)
2008-2014 67.5 81.3 72.6 35.6
2008 31.1 24.4 42.0 17.7
2009 56.1 76.8 55.7 24.8
2010 69.1 91.6 74.1 32.6
2011 75.2 93.8 76.0 34.5
2012 77.0 98.1 83.3 37.3
2013 81.0 95.6 88.1 49.2
2014* 81.1 92.2 86.2 54.3
*2014 has less follow up on patients reported (at data cut off 78.7% of initially reported).
Table 4. Proportion with very good partial remission (VGPR) or better among active myeloma patients with reported follow up after first-line treat-
ment in patients diagnosed 2008-2014 in the Swedish Myeloma Registry, by year of diagnosis and by age group (-65, 66-80, >80 years).   
Patients All ages ≤65 years     66-80 years    >80 years
VGPR or better n (%) n (%) n (%) n (%)
2008-2014 1415 (45.8) 725 (68.3) 575 (38.9) 115 (20.8)
2008 152 (36.1) 87 (55.1) 56 (28.0) 9 (14.3)
2009 173 (40.3) 97 (62.2) 58 (23.4) 18 (23.4)
2010 209 (47.5) 104 (67.5) 86 (43.9) 19 (21.1)
2011 223 (45.4) 123 (72.4) 91 (35.1) 9 (14.5)
2012 223 (46.4) 114 (73.5) 91 (39.6) 18 (18.8)
2013 230 (51.6) 117 (78.0) 94 (46.8) 19 (20.0)
2014* 205 (53.5) 83 (70.3) 99 (50.5) 23 (33.3)
*2014 has less follow up on patients reported (at data cut off 78.7% of initially reported).
the study period. A total of 5.2% of reported MM patients
did not receive any anti-myeloma treatment the first year
after diagnosis and, notably, this involved 11% of patients
over 80 years of age. Bisphosphonates were given in 79%
of patients aged 65 years or under, and in 67% in patients
over 65 years of age.  There was an increase in the use of
one or more of the novel drugs (thalidomide, lenalido-
mide, and bortezomib)  over the study period (Table 3).
Response
The proportion of patients achieving very good partial
remission (VGPR) or better after first-line treatment
increased from 36% in patients diagnosed in 2008 to 54%
in 2014 (P<0.05). The increase was seen in all age groups,
but was more pronounced in patients aged over 80 years,
where the proportion of patients reaching VGPR or better
rose from 14% to 33% (Table 4). 
Survival in all myeloma patients
The 1-, 3-, and 5-year OS   in all patients (SMM+MM)
was 81%, 59%, 42%, and the corresponding RS was 84%,
65%, and 49%, respectively. Survival in 10-year cohorts in
all myeloma patients is shown in Online Supplementary
Table S1 and Figure S2. Early death (<1 year after diagnosis)
was observed in 19% of patients. The 3-year RS was 62%
(95%CI: 59.7-64.6) in women, and 67% (95%CI: 65.0-
69.3) in men. After age standardization, the 3-year RS in
women was 67% (95%CI: 65.1-69.6) and 70% in men
(95%CI: 67.8-71.8). Survival per SMM and MM diagnosis
is shown in Online Supplementary Tables S2 and S3. 
Survival in MM 
In patients with MM and reported follow up (n=3558),
the median OS varied considerably depending on age at
diagnosis, ranging from 7.8 years in patients aged 60 years
and under, to 1.5 years for patients aged 80-89 years
(Online Supplementary Table S4). After a median follow up
of 5.5 years, the median OS in the youngest cohort (<50
years) had  not yet been reached (Figure 2). The median RS
of patients aged 65 years or under was 7.7 years, and 3.4
years in those aged 66 years and over. The 5-year OS and
RS in MM patients was 38.3% and 44.9%, respectively.
The median RS according to ISS stage was 3.2 years and
5.6 years for stages III and II, and 8.2 years for stage I.
Patients with no reported stage had a similar median RS as
stage III patients of three years.
Experiences from the Swedish Myeloma Registry
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Figure 3. Relative survival in active myeloma
(MM) by treatment response in the Swedish
Myeloma Registry in age cohorts: (A) under
65 years of age and (B) 66 years of age and
over. CR: complete remission; VGPR: very
good partial remission; PR: partial remission;
n: number.
A
B
Survival according to response
Overall, better response to first-line treatment was sig-
nificantly associated with superior survival (P<0.05)
(Online Supplementary Table S5). In younger patients, there
was no significant difference in 5-year RS in patients in
PR, VGPR and CR (Figure 3)
Survival according to year of diagnosis
Patients diagnosed in the period 2011-2015 had a trend
to better 1-, 3- and 5-year RS compared to patients diag-
nosed 2008-2010. In patients aged over 65 years, this trend
was more evident than in  younger patients (Online
Supplementary Tables S5 and S6, and Figure S3). In a propor-
tional hazard model of RS by year of diagnosis in all
patients, later calendar year of diagnosis was significantly
associated with improved RS, with an HR of 0.93 (95%CI:
0.92-0.95; P<0.05).
Survival according to treating hospital 
The 1, -3 – and 5-year survival was significantly higher
in university hospitals (Online Supplementary Table S7). In a
proportional hazards model for the RS, the HR was 0.93
(95%CI: 0.87-0.99; P<0.005). Even when adjusting for age,
sex, and ISS-stage, the HR was of borderline statistical sig-
nificance (HR=0.91; 95%CI: 0.83-1.0; P=0.04). Similar
results were obtained when analyzing centers that treated
10 or more MM patients per year (data not shown).
Discussion
In this study from the Swedish Myeloma Registry, we
report incidence, baseline characteristics and survival of an
unselected population comprising more than 97% of all
myeloma patients diagnosed in Sweden in the period
2008-2015. We found an age-adjusted incidence of 6.8 per
100,000 inhabitants; this translates  into 4.8 and 3.2 per
100,000 inhabitants in European and World standards,
respectively. This is higher than figures previously report-
ed by most population-based studies,22,23 but is in agree-
ment with data from a previous large Swedish study.24 The
high age-adjusted incidence might be explained by better
case ascertainment in the elderly. Overall, the proportion
of elderly (65 years and older)  myeloma  patients at diag-
nosis was 72%, and this exceeds the number of reported
elderly patients in most known registries today, but is sup-
ported by population-based data from the Danish
Myeloma Registry25 and a recent report on a large cohort
of European patients.26 We observed a median age of 71
years at diagnosis, which is higher than other myeloma
studies,8 and a steep increase in age-specific incidence
extending to the oldest age cohorts. This indicates that our
population, given the  very high coverage provided by the
Swedish Myeloma Registry, reflects the 'real-world' situa-
tion in myeloma today.
Our study shows encouraging survival rates in the MM
population. In our population-based study, the 5-year OS
was 38%, similar to the data from the EUROCARE
study.27 In a 2014 report from the Mayo clinic based on
1084 MM patients (median age 66 years), the median OS
from diagnosis was 5.2 years and the 6-year OS estimate
was 45%.8 We show that with the increased use of novel
agents there was an improvement in response rates. We
also show that, over the study period, the proportion of
elderly patients receiving novel drugs increased.  The dif-
ference in survival between the different age cohorts was
less pronounced in RS compared to OS, which demon-
strates the importance of including RS in survival analyses
in MM.
In the European Registry data from 2008 (EURO-
CARE),28 a 2% survival advantage was seen in women.
However,  in our more recent study covering the period
from 2008 to 2015, after age standardization, there was no
difference in survival between  men and women.
As expected, and as shown before,29,30 achievement of
response was predictive of prolonged survival. There was
a significant difference in survival in patients aged over 65
years. Given this, we investigated the impact of response
grade on survival in different age cohorts in patients with
MM at diagnosis. The analysis revealed that responding
patients in all age groups had a better outcome than non-
responding patients, and that patients achieving CR had
the longest survival. However, interestingly, in patients
aged 65 years or under there was no significant difference
in survival according to the degree of response (CR, VGPR
or PR).  This is contrary to results from many randomized
studies,31-33 and may indicate that achievement of a high
quality response to first-line treatment may not have the
same importance for survival in a young, unselected
myeloma population where the majority of patients will
eventually receive multiple lines of treatment. 
We found a survival benefit in patients reported from
university hospitals and those hospitals treating a large
number of  MM patients. This is not  surprising given the
speed of progress in diagnostics and the new treatments of
recent years, and has, in fact, also been reported in other
studies.34,35 We could not detect a significant difference in
referral patterns, but in spite of this, our results should be
interpreted with caution, as residual confounding factors
may have influenced outcome. However, this does under-
line the importance of high volume centers with expert
knowledge in MM treatment and  the need for further
studies to monitor access to care for myeloma patients.
The strength of this study is the large,  population-based
cohort and excellent coverage provided by the Swedish
Cancer Registry. Another strength is the public Swedish
health care system. In Sweden, all patients with a diagno-
sis of cancer are treated in public hospitals, enabling pub-
licly financed and equal treatment for all MM patients;
this reduced the risk of information- and selection-bias in
this study. The Swedish Myeloma Registry has provided
valuable information on how new treatments have been
introduced and have been established as standard of care
in clinical practice, leading to improved response rates in
all age groups. Importantly, we have been able to show
that there is good adherence to guidelines in all regions of
Sweden, both with regards to diagnostics and to manage-
ment, and the registry has helped define areas where
improvement is needed. The proportion of patients with
prognostic classification according to ISS and for whom
FISH was performed as part of diagnostic workup has
increased; however, FISH has still not been established as
standard clinical practice in all hospitals. One limitation is
that treatment data on 8% of patients were incomplete,
and some baseline characteristics, such as ISS-stage, were
also missing. In addition, we  do not have detailed data on
cytogenetics and comorbidities. Finally, we did not have
sufficient follow-up data to perform analyses on progres-
sion-free survival after first-line treatment, which is a fur-
ther limitation of this study.
Many large and important studies on characteristics and
C.H. Blimark et al.
512 haematologica | 2018; 103(3)
survival in MM patients are compromised by  the report-
ing bias of referral centers, either because they are  univer-
sity hospital registries with a low median age at MM diag-
nosis, or because they report on selected patients in clini-
cal trials who do not necessarily, therefore,  reflect the
'real-world' scenario in myeloma. Great efforts are being
made to ensure the data available in the Swedish
Myeloma Registry are complete, and to present popula-
tion-based data on management and outcome in Sweden.
However, we can now present a near complete 'real-
world' population of myeloma patients, and show that
the overall incidence and median age is higher than in
most previous studies, indicating a more complete cover-
age of older patients. Myeloma survival in Sweden was
similar to other large registry studies, and responses and
survival improved over the study period. 
Experiences from the Swedish Myeloma Registry
haematologica | 2018; 103(3) 513
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